Global Institute Of Stem Cell Therapy And Research
US: +1-800-914-7836

Category

News

Leading India towards an Immune Future

In August 2020, a 53-year-old COVID patient who was in a comatose state, struggling to hold on to life, was infused with Mesenchymal stem-cells taken from an umbilical cord. The results of this infusion were nothing less than enthralling as the patient recovered significantly in over three weeks.

This medical marvel was made possible by Global Institute of Stem Cell Therapy and Research (GIOSTAR), which is on a mission to administer the safest and most effective stem cell therapies and to deliver the highest quality care through its hospitals.

GIOSTAR was founded on the vision to provide stem cell-based therapy to people suffering from all kinds of degenerative or genetic diseases around the world. The company is evidently a leader in developing cutting edge stem cell-based technology, supported by leading scientists with pioneering publications in the area of stem cell biology. GIOSTAR was also one of the first company/research institute in the world which received USA-FDA approval in April 2020 to treat COVID-19 patients with stem cells.

The company’s primary focus is on discovering and developing a cure for human diseases through state-of-the-art and unique stem cell-based therapies and products. The company’s intellectual property, intellectual assets and technology have been developed over its team working on research projects funded to the tune of more than several hundred million dollars.

GIOSTAR is a coalition of esteemed and illustrious scientific minds in the field of genetic and stem cell science. The company’s team members have been involved in the development and utilization of stem cell based clinical protocols related to malignant and non-malignant diseases for the last 20 years.

The company’s leaders are associated with leading universities and research institutes of USA. GIOSTAR is affiliated with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute for Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA, Harvard Medical School, Imperial College, London.

“Our team has developed several research collaborations and has an extensive research experience in the stem cell therapy which is documented by several publications in revered scientific journals,” says Dr Anand Srivastava, the Chairman and Co-founder of GIOSTAR.

Dr Srivastava’s profound success has its root in his unique background and expertise in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research.

There are many scientists who can work in a narrowly defined field, but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as stem cell biology, cancer, and gene therapy. Dr Srivastava’s wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR’s projects for stem cell transplant, cancer, and gene therapy research. Dr Srivastava is also serving as stem cell director for the government of Gujarat, India and is in the process of establishing the stem cell program for Gujarat, Government of India.

The team at GIOSTAR is reaching heights of success also under the able leadership of Mr. Deven Patel, the CEOPresident and Cofounder. Mr. Patel was honoured with USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the world. He was also bestowed with the Asian Heritage Award for his business leadership in the field of stem cell science.

GIOSTAR, under the leadership of Mr. Patel, is heading the development of stem cell transplant program for four different State Governments in India with total population of approx. 155 million. The company, in collaborations with Government of Gujarat, India, has founded the world’s largest state-of-the-art stem cell treatment hospital in India. GIOSTAR is also in process of developing additional facilities in China, Thailand, Colombia, Bahamas, Dubai, and Australia.

Talking about how GIOSTAR successfully found the solution to treat COVID-19 related health issues, Dr Srivastava explains, “COVID-19 infection leads to uncontrolled release of proinflammatory cytokines known as ‘cytokine storms’ that potentially lead to fatal damage of many organs of the body. MSCs have specific characteristics that, when infused in the bloodstream, neutralize proinflammatory cytokines (through ‘immunomodulation’), down-regulate the inflammatory gene actions and send messages to regenerate damaged lung and other tissues, which may help in managing COVID-19.” GIOSTAR is also gearing up to start its clinical trial for patients with aftereffects of COVID-19 on lungs and other organs.

We asked Dr Srivastava about his opinion on the necessity for businesses to align their offerings with newer technological developments, especially when it comes to changing industry trends and customer preferences, to which he replied, “Scientific research is an ever-evolving process. GIOSTAR being hard core research organization allows it to be at the forefront of new innovations and possible cure for several incurable disease. This same mindset has made us one of the first research institutes in the world to get very early approval form USA-FDA to treat COVID-19 patients with stem cells.”

Mr. Patel on the other hand shared a few tokens of knowledge through the commercial perspective of regenerative medicine development, he says, “The pharma and scientific research businesses are very competitive, at very high level of science and at very high cost. Therefore, a simple advice to aspiring entrepreneurs is to first get their ducks in the row and get your finances figured out way in advance, otherwise it is very easy to bankrupt the company in this volatile economy.”

GIOSTAR’s plan to continue scaling its operation, keeping in mind the unpredictable future, can be viewed to be agile and ready to run. Pertaining to stable finances, the company’s pipeline of several technologies is very robust and in line with its projections. GIOSTAR is poised to be the largest stem cell research and therapy company on the earth. The company is already becoming a synonym for the stem cell treatment.

Read More : https://insightscare.com/giostar-leading-india-towards-an-immune-future/

GIOSTAR Announces FDA Approval Under Compassionate Use for a COVID-19 with Stem Cells

GIOSTAR Received FDA Approval Under Expanded Access For Use of Stem Cells to Treat COVID-19 Patients 

Under expanded access, also known as compassionate use, the U.S. Food and Drug Administration (FDA) has approved GIOSTAR the emergency use of stem cell therapy to treat acute inflammation of the lungs in hospitalized patients diagnosed with COVID-19. Expanded access allows patients to receive stem cell therapy on a case-by-case basis outside of a conventional clinical trial as deemed appropriate by the treating physician, the GIOSTAR medical director and the FDA. Each patient will be assessed to determine if stem cell therapy is appropriate and a separate Investigational New Drug (IND) application will be filed for the FDA’s approval every single time. Patients will be evaluated after the infusion of the stem cells and the outcome of the treatment will be submitted to the FDA regularly.

 Treatment of COVID-19 patients with mesenchymal stem cells (MSCs) has been shown to be beneficial in a number of studies from USA, Israel, China and UAE[Admin1] . In the U.S., the FDA approved a clinical trial to study use of umbilical cord stem cells in the treatment of COVID-19 patients https://newsroom.baptisthealth.net/press-release/fda-approves-covid-19-trial-after-successful-emergency-use-of-umbilical-stem-cells-from-restem/

 COVID-19 infection causes an acute flow of inflammatory cytokines like IL-6, GCSF, IP10, MCP-1, MIP1A, and TNF-α in the lungs, which cause and promote formation of microthrombi.  These microthrombi can block normal flow of blood in any part of the body leading to pathogenesis in the afflicted organ. This could be a very probable reason as COVID-19 has been shown to affect any part of the body like brain, heart, kidneys, intestines and of course the lungs.

The MSCs, known for its immunomodulatory character and secret a lot of anti-inflammatory cytokines and suppress the pro-inflammatory cytokines. After infusion in COVID-19 patients, MSCs have been shown to have high expression of anti-inflammatory and trophic factor genes like HGF, LIF, NOA1, VEGF, EGF, BNDF and NGF to name a few. These anti-inflammatory cytokines may help alleviate the COVID-19 symptoms. Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia Aging and disease (2020) 11: 216-228;Cytokine release syndrome in severe COVID-19 Science (2020) 368-473-474

Groundbreaking research provides a promising potential alternative to devastating pandemic

Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in stem cell research, is pleased to announce that they have received an approval for COVID-19 clinical trial, led by their Medical Director Dr. Prabhat Soni. GIOSTAR will conduct the trials using stem cells to treat COVID-19 patients, under the approval of the United States Food and Drug Administration (FDA) “expanded access for compassionate use” program. The Institute is exploring a promising alternative approach to the devastating disorder, which leverages the anti-inflammatory properties of mesenchymal stem cells (MSCs). According to Dr. Soni, the investigation is based upon two decades of stem cell research by GIOSTAR Co-Founder, Chairman and Chief Scientific Officer Dr. Anand Srivastava.

Untitled design (3)

The COVID-19 pandemic has resulted in unprecedented disruption, with more than 3 million cases and 200,000 deaths reported worldwide as of May 1, 2020 – a figure that is projected to grow exponentially in the weeks ahead. Caused by a pathogenic virus known as SARS-CoV-2, the infection induces a broad range of responses in humans: some patients are asymptomatic, others develop mild flu-like discomfort, and still others suffer from severe pneumonia. Physicians have resorted to numerous traditional and unconventional therapies to combat the effects of COVID-19. These therapies – which include antibiotics and plasma therapy – have proven largely ineffective in managing the spread of the pandemic.

A Novel Approach to Inflammation

Given these challenges, there has unsurprisingly been a surge in clinical trials for use of MSC’s to combat COVID-19. Cedars-Sinai Medical Center recently cited studies that “support the notion that cell therapy can attenuate inflammation, which may be attractive in COVID-19.” One study by an international coalition of researchers from China, United States, India, France, and other countries appeared in Aging and Disease, showing full recovery of seven COVID-19 patients 2 weeks after receiving intravenous (IV) administration of allogeneic (sourced externally from donors) MSCs.

COVID-19 is induced by a release of signaling molecules known as cytokines – small protein molecules released by immune cells to orchestrate the “attack-and-destroy” mode of the host’s immune system response to pathogens. Cytokines are either proinflammatory (“bad”) or anti-inflammatory (“good”), meaning that they either increase or decrease levels of inflammation in the body. In the case of COVID-19, an uncontrolled immune response leads to a “cytokine storm,” dramatically raising levels of IL-6, IL-8, and TNF-alpha and other proinflammatory proteins. The immune system then goes into “overdrive” mode, thereby causing potentially fatal damage to the patient’s own tissues and organs.

Drs. Srivastava and Soni sought to leverage and apply extensive research demonstrating the effectiveness of MSCs in combating the respiratory symptoms and cytokine storms associated with COVID-19. “The cells have specific characteristics that, when infused in the bloodstream,” Dr. Srivastava explained in an educational video, “neutralize the proinflammatory cytokines, down-regulate the inflammatory gene actions (through ‘immunomodulation’), and send messages to regenerate damaged lung tissues.”

Seeing great potential in this therapeutic approach, the FDA approved MSC-based treatment for use in the most severe cases of COVID-19, under their “expanded access for compassionate use” program. The first patients will be treated in New York City. The city has been among the most severely impacted regions of the country, with more than 170,000 confirmed cases of COVID-19 and 13,000 deaths as of May 1, 2020.

“GIOSTAR appreciates the FDA for their timely action in approving the protocol,” noted Dr. Soni. “We’re looking forward to sharing the findings from our studies with the world, which may help save many lives in the future.”

About GIOSTAR

GIOSTAR is the pioneer and established leader in the field of stem cell research. Under the leadership of Co-Founders Dr. Anand Srivastava and Deven Patel, the San Diego-based Institute has a tradition of groundbreaking research in stem cell science spanning more than two decades.

Related Links :
http://www.giostar.com/

https://www.prnewswire.com/news-releases/giostar-announces-fda-approval-under-compassionate-use-for-a-covid-19-clinical-trial-with-stem-cells-301051830.html

CHANDIGARH, India, Feb. 5, 2020 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), a leading provider of regenerative medicine, is proud to announce the inauguration of a new stem cell / cancer research and therapy center in Chandigarh, India. This facility represents the latest milestone in global expansion efforts spearheaded by GIOSTAR in IndiaMexicothe United States, and numerous other countries.

GIOSTAR Chandigarh occupies 4 stories and 12,000 square feet, with a sleek, modern design that “reflects the cutting edge, elite science that GIOSTAR has been delivering for over two decades,” according to GIOSTAR Co-Founder and CEO Deven Patel. Following the recent opening of a center in New Delhi, it is the most recent in a series of hospitals being launched throughout the country. Future plans for expansion include Kolkata and Bangalore.

Chandigarh is noteworthy for having been the first planned city in India, designed by famed Swiss architect Le Corbusier. Located in Northern India, it is one of the country’s wealthiest cities, ranking the highest for Human Development Index (HDI) (a measurement of standard of living, literacy rates, and life expectancy). In addition to its verdant gardens and abundant shopping and dining offerings, Chandigarh is home to several prestigious research institutions such as Panjab University and Baba Farid Medical University.

Several key luminaries in the field of medical research, including Drs. S. S. GillSanjeev PuriSeemha Rai, and Amandeep Singh participated in the inauguration, delivering remarks about the state of regenerative medicine in India. “GIOSTAR is proud of our tradition of excellence in research,” noted GIOSTAR Co-Founder and Chairman Dr. Anand Srivastava, “and we are privileged to welcome such influential leaders in the field on this auspicious occasion.”

Continued Collaboration, Sustained Impact
GIOSTAR has long played a central role in the evolution of regenerative medicine within India. This began with the 2011 launch of the world’s first dedicated stem cell therapy hospital in Gujarat, resulting from a landmark partnership with Prime Minister of India Shri Narendra Modi.  GIOSTAR is also collaborating with a few state governments of India. “These partnerships have been very beneficial,” noted Patel, “as they enable GIOSTAR to deliver regenerative therapies to millions of people suffering from degenerative disorders and cancer.”

Additional highlights of GIOSTAR’s worldwide efforts include:

  • Launch of a stem cell therapy center in Cancun Rivera, Mexico, regarded as one of the world’s premier tourist destinations
  • Collaboration with large pharmaceutical company in China to launch clinical trials for cerebral palsy for children
  • Conditional approval for Type 2 Diabetes clinical trial in Bahamas, where nearly 15% of the population suffers from the disease
  • In-depth discussions between delegations of Ahmedabad, India and Kobe, Japan, to foster additional investment opportunities between the two “sister cities”
  • Process of FDA approval for clinical trials for Type 2 Diabetes and other disorders in the United States

“2020 will be a very bright year, with unlimited potential for the field of regenerative medicine,” noted Patel. “There’s a great deal of work yet to be done, however, and GIOSTAR will continue leading the charge – in Chandigarh, and around the world.”

About GIOSTAR

GIOSTAR is the pioneer and established leader in the field of regenerative medicine for sports injuries, joint arthritis afflictions, and additional degenerative conditions. The Institute’s advanced techniques and protocols have been extensively researched and developed by Dr. Anand Srivastava and GIOSTAR’s leading scientists for more than 20 years.

 

Source : https://www.prnewswire.com/news-releases/giostar-launches-stem-cell–cancer-research-and-therapy-center-in-chandigarh-india-300999284.html

PLAYA DEL CARMEN, MexicoJan. 14, 2020 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the pioneer in stem cell-based technologies, is proud to announce the launch of a new stem cell therapy center in the Cancun Riviera, Mexico. With this announcement, GIOSTAR further bolsters its leadership in the global medical tourism market, which is projected to grow at a compound annual growth rate (CAGR) of 16.1% for the next 5 years. The Cancun Riviera center highlights GIOSTAR’s continued expansion of its presence in Mexico, which also includes facilities in Los Algodones and Guadalajara.

Stem cells are unspecialized unique body cells that may help patients better manage symptoms of multiple sclerosis, arthritis, and other degenerative diseases. In addition to its clinics such as GIOSTAR Cancun Riviera, the GIOSTAR management team collaborates closely with leading government agencies to create stem cell therapy and research programs in JapanChinaCosta Rica, and Thailand. “This center is a testament to the commitment from the thousands of patients GIOSTAR has treated throughout the world,” noted GIOSTAR CEO and Co-Founder Deven Patel. “It’s only because of their trust in our capabilities that we’ve been able to grow our infrastructure.”

GIOSTAR Cancun Riviera offers several key benefits, including:

  • Great vacation destinationCancun has long been regarded as one of the world’s most attractive vacation destinations, with beautiful beaches, vibrant nightlife, and ample shopping opportunities.
  • Easy access: the GIOSTAR facility is located near Mexico’s second largest airport (Cancun International Airport), making it accessible via direct flights from numerous cities throughout the world.
  • Therapies backed by decades of research: GIOSTAR Cancun Riviera’s highly skilled professionals are trained extensively in the lab techniques and protocols developed by GIOSTAR Chairman and Co-Founder, Dr. Anand Srivastava.

Due to these advantages, Mr. Patel remarked that “this center helps GIOSTAR to continue executing on our mission to make the most advanced, elite, and expensive science available to the masses.”

As with the GIOSTAR center in Los Algodones, Mexico, GIOSTAR Cancun Riviera is integrated with other facilities such as the Sani Dental Group dental clinic. This provides patients the opportunity to receive comprehensive health care while taking advantage of the amenities offered in the surrounding Playa del Carmen area.

Additionally, the colors of the walls and furniture, the wood used in the fixtures, and other aesthetic elements of the center are closely aligned with those of the Mayan Riviera. “We wanted the center to look as authentic (yet modern) as possible,” noted GIOSTAR Mexico Chief Operating Officer Alejandro Gutiérrez. “The Cancun Riviera facility reflects Dr. Srivastava’s belief that stem cell therapy patients will maximize their success rate when they’re in a relaxed state of mind.”

Upcoming plans for 2020 include an “official inauguration event” in February, along with tentative plans to open an additional center in Mexico.

About GIOSTAR

GIOSTAR is the pioneer and established leader in the field of regenerative medicine. Under Dr. Anand Srivastava’s leadership, the San Diego-based Institute has a tradition of groundbreaking research in the field of stem cell science spanning more than two decades.

 

Source : https://www.prnewswire.com/news-releases/giostar-launches-stem-cell-therapy-center-in-cancun-riviera-300986482.html

GIOSTAR Chairman and Co-founder Dr. Anand Srivastava and Vice Chancellor, Dr. Mohammed Basheer of Calicut University,  Kerala Signed an Agreement to Develop Advanced Stem Cell Center under the direction of GIOSTAR

 

 

Make An Inquiry

We are here to help you

WordPress Video Lightbox